KPTI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.98%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $15,677.99

Karyopharm Therapeutics Insider Trading History Chart

Karyopharm Therapeutics Share Price & Price History

^$5.91

▲ +0.45 (8.24%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Karyopharm Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/1/2025	Kristin Abate	CAO	Sell	362	$6.30	$2,280.60	10,046
9/15/2025	Kristin Abate	CAO	Sell	23	$6.43	$147.89	10,408
9/15/2025	Michael Mano	SVP	Sell	234	$6.43	$1,504.62	21,425
9/15/2025	Reshma Rangwala	EVP	Sell	408	$6.43	$2,623.44	29,390
9/15/2025	Sohanya Roshan Cheng	EVP	Sell	325	$6.43	$2,089.75	35,856
9/15/2025	Stuart Poulton	EVP	Sell	401	$6.43	$2,578.43	27,710
9/3/2025	Kristin Abate	CAO	Sell	12	$6.78	$81.36	9,463
7/29/2025	Stuart Poulton	EVP	Sell	191	$4.37	$834.67	27,223
7/22/2025	Kristin Abate	CAO	Sell	238	$4.00	$952.00	9,475
4/23/2025	Reshma Rangwala	EVP	Sell	419	$6.17	$2,585.23	28,853
10/4/2024	Richard A Paulson	CEO	Sell	240	$13.20	$3,168.00	75,707
8/6/2024	Richard A Paulson	CEO	Sell	240	$13.95	$3,348.00	76,192
7/30/2024	Stuart Poulton	EVP	Sell	192	$15.90	$3,052.80	21,775
7/5/2024	Richard A Paulson	CEO	Sell	241	$12.75	$3,072.75	76,432
6/7/2024	Deepika Pakianathan	Director	Sell	15,436	$14.25	$219,963.00
6/5/2024	Deepika Pakianathan	Director	Sell	31,202	$14.40	$449,308.80	225
6/4/2024	Michael Mason	CFO	Sell	43	$14.85	$638.55	26,540
6/4/2024	Richard A Paulson	CEO	Sell	239	$14.85	$3,549.15	76,673
6/3/2024	Deepika Pakianathan	Director	Sell	24,049	$15.00	$360,735.00	747
5/31/2024	Deepika Pakianathan	Director	Sell	13,626	$14.25	$194,170.50	979
5/6/2024	Richard A Paulson	CEO	Sell	238	$16.95	$4,034.10	76,913
4/22/2024	Reshma Rangwala	EVP	Sell	452	$17.55	$7,932.60	22,862
4/4/2024	Richard A Paulson	CEO	Sell	237	$19.35	$4,585.95	77,151
3/5/2024	Richard A Paulson	CEO	Sell	238	$19.50	$4,641.00	77,389
2/29/2024	Michael Mano	SVP	Sell	1,131	$17.55	$19,849.05	18,761
2/29/2024	Michael Mason	CFO	Sell	1,845	$17.55	$32,379.75	26,994
2/29/2024	Reshma Rangwala	EVP	Sell	1,044	$17.55	$18,322.20	23,712
2/29/2024	Richard A Paulson	CEO	Sell	5,364	$17.55	$94,138.20	78,918
2/27/2024	Michael Mason	CFO	Sell	169	$19.80	$3,346.20	16,293
2/15/2024	Stuart Poulton	EVP	Sell	389	$19.95	$7,760.55	10,918
2/6/2024	Michael Mason	CFO	Sell	280	$23.85	$6,678.00	16,463
2/6/2024	Richard A Paulson	CEO	Sell	267	$23.85	$6,367.95	54,763
1/4/2024	Richard A Paulson	CEO	Sell	274	$12.30	$3,370.20	52,231
12/4/2023	Richard A Paulson	CEO	Sell	241	$11.85	$2,855.85	52,505
11/6/2023	Richard A Paulson	CEO	Sell	240	$13.80	$3,312.00	52,746
10/4/2023	Richard A Paulson	CEO	Sell	239	$19.05	$4,552.95	52,987
9/12/2023	Garen G. Bohlin	Director	Buy	2,742	$18.30	$50,178.60	3,009
9/1/2023	Michael Mano	SVP	Sell	259	$19.95	$5,167.05	9,482
9/1/2023	Michael Mason	CFO	Sell	460	$19.95	$9,177.00	15,854
9/1/2023	Sohanya Roshan Cheng	EVP	Sell	494	$19.95	$9,855.30	13,605
8/7/2023	Richard A Paulson	CEO	Sell	248	$25.80	$6,398.40	53,467
7/28/2023	Stuart Poulton	EVP	Sell	189	$25.50	$4,819.50	10,419
7/5/2023	Richard A Paulson	CEO	Sell	235	$25.80	$6,063.00	53,716
6/8/2023	Sohanya Roshan Cheng	EVP	Sell	122	$35.25	$4,300.50	14,100
5/4/2023	Richard A Paulson	CEO	Sell	253	$50.25	$12,713.25	54,187
4/20/2023	Reshma Rangwala	EVP	Sell	451	$60.75	$27,398.25	10,548
4/4/2023	Richard A Paulson	CEO	Sell	233	$59.55	$13,875.15	54,441
3/6/2023	Richard A Paulson	CEO	Sell	233	$47.40	$11,044.20	54,674
3/1/2023	Michael Mason	CFO	Sell	747	$45.45	$33,951.15	16,357
3/1/2023	Richard A Paulson	CEO	Sell	2,202	$45.45	$100,080.90	54,908
3/1/2023	Sohanya Roshan Cheng	EVP	Sell	749	$45.45	$34,042.05	14,045
3/1/2023	Stephen Mitchener	SVP	Sell	423	$45.45	$19,225.35	8,554
2/15/2023	Stuart Poulton	EVP	Sell	391	$47.85	$18,709.35	4,275
1/4/2023	Richard A Paulson	CEO	Sell	261	$49.05	$12,802.05	40,573
12/5/2022	Richard A Paulson	CEO	Sell	232	$77.55	$17,991.60	40,835

SEC Filings (Institutional Ownership Changes) for Karyopharm Therapeutics (NASDAQ:KPTI)

66.44% of Karyopharm Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Karyopharm Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/14/2025	ADAR1 Capital Management LLC	25,000	$0.16M	0.0%	N/A	0.147%
11/14/2025	Bridgeway Capital Management LLC	34,873	$0.23M	0.0%	-7.8%	0.205%
11/14/2025	Silverback Asset Management LLC	40,000	$0.26M	0.0%	-42.9%	0.235%
11/7/2025	Vanguard Group Inc.	408,222	$2.67M	0.0%	-21.2%	4.708%
8/15/2025	Bridgeway Capital Management LLC	37,836	$0.16M	0.0%	N/A	0.436%
8/15/2025	Bank of America Corp DE	168,534	$0.73M	0.0%	+26.8%	1.944%
8/13/2025	Baird Financial Group Inc.	10,532	$45K	0.0%	N/A	0.122%
8/13/2025	Silverback Asset Management LLC	70,000	$0.30M	0.0%	+40.0%	0.810%
8/12/2025	XTX Topco Ltd	13,056	$56K	0.0%	N/A	0.151%
8/8/2025	Geode Capital Management LLC	91,841	$0.40M	0.0%	-7.8%	1.063%
6/27/2025	Goldman Sachs Group Inc.	85,410	$0.32M	0.0%	-93.6%	0.989%
5/19/2025	Jane Street Group LLC	11,420	$43K	0.0%	-98.5%	0.132%
5/16/2025	Goldman Sachs Group Inc.	85,410	$0.32M	0.0%	-93.6%	0.997%
5/16/2025	Adage Capital Partners GP L.L.C.	421,322	$1.58M	0.0%	-93.3%	4.916%
5/15/2025	Birchview Capital LP	27,985	$0.11M	0.1%	-93.3%	0.327%
5/15/2025	Palo Alto Investors LP	324,032	$1.21M	0.2%	-93.4%	3.781%
5/14/2025	T. Rowe Price Investment Management Inc.	139,646	$0.52M	0.0%	N/A	1.629%
5/13/2025	Altium Capital Management LLC	49,333	$0.19M	0.4%	-93.3%	0.576%
5/5/2025	C WorldWide Group Holding A S	100,000	$0.37M	0.0%	-93.3%	1.167%
4/29/2025	Bank of New York Mellon Corp	11,086	$41K	0.0%	-93.3%	0.129%
2/17/2025	Velan Capital Investment Management LP	40,000	$27K	0.0%	N/A	0.032%
2/17/2025	Two Sigma Advisers LP	76,600	$52K	0.0%	+145.5%	0.061%
2/17/2025	Two Sigma Investments LP	137,786	$93K	0.0%	+60.3%	0.109%
2/17/2025	Shay Capital LLC	172,153	$0.12M	0.0%	N/A	0.136%
2/17/2025	Millennium Management LLC	1,154,414	$0.78M	0.0%	-8.0%	0.915%
2/17/2025	Focus Partners Wealth	45,818	$31K	0.0%	N/A	0.036%
2/17/2025	D. E. Shaw & Co. Inc.	229,685	$0.16M	0.0%	-78.1%	0.182%
2/17/2025	Cubist Systematic Strategies LLC	328,807	$0.22M	0.0%	-33.7%	0.261%
2/17/2025	Bank of America Corp DE	161,708	$0.11M	0.0%	-29.4%	0.128%
2/17/2025	BNP Paribas Financial Markets	1,313,893	$0.89M	0.0%	-33.7%	1.041%
2/14/2025	Jane Street Group LLC	748,306	$0.51M	0.0%	+265.5%	0.593%
2/14/2025	Northern Trust Corp	283,729	$0.19M	0.0%	+23.5%	0.225%
2/14/2025	Birchview Capital LP	419,832	$0.28M	0.2%	-10.6%	0.333%
2/14/2025	Opti Capital Management LP	125,000	$85K	0.0%	N/A	0.099%
2/14/2025	Adage Capital Partners GP L.L.C.	6,319,842	$4.27M	0.0%	+46.3%	5.008%
2/14/2025	Price T Rowe Associates Inc. MD	64,300	$44K	0.0%	-52.3%	0.051%
2/14/2025	Silverarc Capital Management LLC	595,990	$0.40M	0.1%	+6.7%	0.472%
2/14/2025	Eversept Partners LP	2,088,757	$1.41M	0.1%	-62.4%	1.655%
2/14/2025	TD Waterhouse Canada Inc.	48,049	$32K	0.0%	N/A	0.038%
2/13/2025	Marshall Wace LLP	2,401,413	$1.63M	0.0%	+15.3%	1.903%
2/13/2025	Renaissance Technologies LLC	1,202,590	$0.81M	0.0%	-3.1%	0.953%
2/12/2025	Geode Capital Management LLC	1,392,314	$0.94M	0.0%	+2.7%	1.103%
11/19/2024	Barclays PLC	95,767	$79K	0.0%	-89.0%	0.076%
11/16/2024	Geode Capital Management LLC	1,355,392	$1.13M	0.0%	+3.3%	1.082%
11/15/2024	Barclays PLC	95,767	$79K	0.0%	-89.0%	0.076%
11/15/2024	Jane Street Group LLC	204,750	$0.17M	0.0%	-86.8%	0.163%
11/15/2024	State Street Corp	409,510	$0.34M	0.0%	-9.8%	0.327%
11/15/2024	Point72 Asia Singapore Pte. Ltd.	82,446	$68K	0.0%	-50.1%	0.066%
11/13/2024	BNP Paribas Financial Markets	1,982,354	$1.65M	0.0%	-12.8%	1.582%
11/13/2024	FMR LLC	369,723	$0.31M	0.0%	+26.1%	0.295%
11/5/2024	GSA Capital Partners LLP	1,775,700	$1.47M	0.1%	+80.6%	1.424%
10/10/2024	Exchange Traded Concepts LLC	218,791	$0.18M	0.0%	+34.9%	0.176%
9/16/2024	Point72 DIFC Ltd	35,939	$31K	0.0%	N/A	0.029%
9/16/2024	Cubist Systematic Strategies LLC	568,975	$0.49M	0.0%	N/A	0.456%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	165,318	$0.14M	0.0%	N/A	0.133%
8/15/2024	AQR Capital Management LLC	748,020	$0.65M	0.0%	+494.5%	0.600%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	165,318	$0.14M	0.0%	N/A	0.133%
8/14/2024	Cubist Systematic Strategies LLC	568,975	$0.49M	0.0%	N/A	0.457%
8/14/2024	Point72 DIFC Ltd	35,939	$31K	0.0%	N/A	0.029%
8/14/2024	Marshall Wace LLP	2,580,863	$2.25M	0.0%	-0.6%	2.071%
8/12/2024	XTX Topco Ltd	140,576	$0.12M	0.0%	-42.1%	0.113%
8/9/2024	Renaissance Technologies LLC	756,227	$0.66M	0.0%	-16.6%	0.607%
8/6/2024	Acadian Asset Management LLC	194,168	$0.17M	0.0%	N/A	0.156%
8/6/2024	Los Angeles Capital Management LLC	354,020	$0.31M	0.0%	-8.6%	0.284%
7/26/2024	Bank of New York Mellon Corp	166,315	$0.14M	0.0%	-65.9%	0.133%
5/17/2024	Ikarian Capital LLC	409,355	$0.62M	0.1%	+2.3%	0.348%
5/10/2024	Vanguard Group Inc.	8,338,401	$12.59M	0.0%	-4.3%	7.160%
5/3/2024	GSA Capital Partners LLP	1,299,151	$1.96M	0.2%	-44.4%	1.115%
4/24/2024	Simplicity Wealth LLC	44,011	$66K	0.0%	N/A	0.038%
2/15/2024	Birchview Capital LP	469,832	$0.41M	0.3%	-17.8%	0.410%
2/12/2024	Monashee Investment Management LLC	132,435	$0.12M	0.0%	N/A	0.116%
2/8/2024	Panagora Asset Management Inc.	227,445	$0.20M	0.0%	N/A	0.199%
2/7/2024	BNP Paribas Financial Markets	1,769,184	$1.53M	0.0%	+6.5%	1.545%
2/6/2024	Los Angeles Capital Management LLC	391,540	$0.34M	0.0%	N/A	0.342%
1/29/2024	Simplicity Solutions LLC	37,938	$33K	0.0%	N/A	0.033%
1/25/2024	Bleakley Financial Group LLC	37,938	$33K	0.0%	N/A	0.033%
1/12/2024	SG Americas Securities LLC	73,430	$64K	0.0%	+295.0%	0.064%
1/5/2024	Exchange Traded Concepts LLC	115,864	$100K	0.0%	+34.0%	0.101%
11/15/2023	Tejara Capital Ltd	1,077,388	$1.44M	0.8%	-5.8%	0.941%
11/15/2023	GSA Capital Partners LLP	568,298	$0.76M	0.1%	N/A	0.496%
11/14/2023	Avidity Partners Management LP	8,298,570	$11.12M	0.4%	-0.9%	7.246%
11/13/2023	Silverarc Capital Management LLC	561,955	$0.75M	0.2%	+8.3%	0.491%
11/13/2023	Tejara Capital Ltd	1,077,388	$1.44M	1.1%	-5.8%	0.941%
11/8/2023	Wade G W & Inc.	45,140	$60K	0.0%	N/A	0.039%
11/7/2023	Quantbot Technologies LP	21,699	$29K	0.0%	-60.1%	0.019%
11/7/2023	Barclays PLC	1,152,298	$1.54M	0.0%	+4.2%	1.008%
10/18/2023	Exchange Traded Concepts LLC	86,484	$0.12M	0.0%	+30.2%	0.076%
8/15/2023	Silverarc Capital Management LLC	518,985	$0.93M	0.3%	-66.3%	0.454%
8/14/2023	Prelude Capital Management LLC	15,933	$29K	0.0%	-62.4%	0.014%
8/14/2023	Graham Capital Management L.P.	62,414	$0.11M	0.0%	N/A	0.055%
8/11/2023	Rubric Capital Management LP	919,196	$1.65M	0.1%	-79.3%	0.804%
8/11/2023	Tejara Capital Ltd	1,143,991	$2.05M	1.0%	+128.1%	1.000%
8/11/2023	Platinum Investment Management Ltd.	500,000	$0.90M	0.0%	N/A	0.437%
8/11/2023	ExodusPoint Capital Management LP	2,382,451	$4.27M	0.0%	N/A	2.083%
8/9/2023	BNP Paribas Arbitrage SNC	461,096	$0.83M	0.0%	+24.8%	0.403%
8/8/2023	AlphaCentric Advisors LLC	810,000	$1.45M	0.8%	+237.5%	0.708%
8/8/2023	Candriam S.C.A.	1,435,694	$2.57M	0.0%	-6.5%	1.255%
8/7/2023	Principal Financial Group Inc.	32,838	$59K	0.0%	-32.8%	0.029%
8/7/2023	Acadian Asset Management LLC	98,946	$0.18M	0.0%	N/A	0.087%
8/4/2023	American International Group Inc.	54,514	$98K	0.0%	+45.1%	0.048%

Data available starting January 2016

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $5.91

$5.37

$6.05

50 Day Range

MA: $5.88

$5.16

$6.55

52 Week Range

Now: $5.91

$3.51

$12.45

Volume

134,739 shs

Average Volume

112,035 shs

Market Capitalization

$100.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Who are the company insiders with the largest holdings of Karyopharm Therapeutics?: Karyopharm Therapeutics' top insider shareholders include:
Richard A Paulson (CEO)
Sohanya Roshan Cheng (EVP)
Reshma Rangwala (EVP)
Stuart Poulton (EVP)
Michael Mason (CFO)
Michael Mano (SVP)
Kristin Abate (CAO)
Deepika Pakianathan (Director)
Learn More about top insider investors at Karyopharm Therapeutics.
Who are the major institutional investors of Karyopharm Therapeutics?: Karyopharm Therapeutics' top institutional shareholders include:
JPMorgan Chase & Co. — 0.00%
Vanguard Group Inc. — 4.71%
Susquehanna International Group LLP — 0.00%
Citadel Advisors LLC — 0.00%
Silverback Asset Management LLC — 0.23%
Bridgeway Capital Management LLC — 0.20%
Learn More about top institutional investors of Karyopharm Therapeutics stock.
Which major investors are selling Karyopharm Therapeutics stock?: Within the previous quarter, KPTI stock was sold by these institutional investors:
Vanguard Group Inc.
Silverback Asset Management LLC
Bridgeway Capital Management LLC
Within the last year, company insiders that have sold Karyopharm Therapeutics company stock include:
Richard A Paulson (CEO)
Sohanya Roshan Cheng (EVP)
Reshma Rangwala (EVP)
Stuart Poulton (EVP)
Michael Mason (CFO)
Learn More investors selling Karyopharm Therapeutics stock.
Which major investors are buying Karyopharm Therapeutics stock?: In the last quarter, KPTI stock was purchased by institutional investors including:
JPMorgan Chase & Co.
Susquehanna International Group LLP
Group One Trading LLC
Citadel Advisors LLC
ADAR1 Capital Management LLC
National Bank of Canada FI
Belvedere Trading LLC